Latest News Year 2024 2023 2022 2021 2020 2019 2018 2017 2016 Search Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations Nov 25 2020 Senhwa Announces Multiple IND application submissions to U.S. FDA for Silmitasertib as a Potential Treatment for COVID-19 Nov 02 2020 Coronavirus Breakthrough: Senhwa Reports First eIND Silmitasertib Treated Severe COVID-19 Patient - Discharged Following Five Days of Treatment Sep 11 2020 Senhwa Biosciences’s Silmitasertib Receives Rare Pediatric Disease Designation from U.S. FDA for Treatment of Recurrent Sonic Hedgehog Medulloblastoma Jul 06 2020 Coronavirus Breakthrough: New Study Highlights Senhwa Biosciences Silmitasertib as Potential Treatment for COVID-19 Jul 02 2020 Senhwa’s Abstract of Silmitasertib for the Treatment of Basal Cell Carcinoma Clinical Trial Accepted for 2020 ASCO Online Publication May 14 2020 Senhwa Biosciences Silmitasertib Named as Potential Covid-19 Therapy Mar 31 2020 Senhwa Biosciences Reports Positive Phase 1 Data of CX-5461 in Patients With Advanced Solid Tumors at 2019 SABCS Dec 13 2019 1 2 3 4 5 6 7 8